LFchimera, a hybrid combining lactoferricin and lactoferrampin sequences, showed stronger bactericidal activity and better resistance to salt-induced inactivation than either parent peptide — a superior hybrid antibiotic.
Key findingLFchimera (lactoferricin-lactoferrampin hybrid) showed stronger bactericidal activity and greater ionic strength tolerance than either parent peptide,
What the researchers found
LFchimera (lactoferricin-lactoferrampin hybrid) showed stronger bactericidal activity and greater ionic strength tolerance than either parent peptide, demonstrating synergistic improvement from combining two antimicrobial domains of lactoferrin into a single chimeric peptide.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides.
Biochimie, 91(1), 123-32
Citation
Bolscher, Jan G M; Adão, Regina; Nazmi, Kamran; van den Keybus, Petra A M; van 't Hof, Wim; Nieuw Amerongen, Arie V; Bastos, Margarida; Veerman, Enno C I. (2009). Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides.. Biochimie, 91(1), 123-32. https://doi.org/10.1016/j.biochi.2008.05.019